Funder
Innovative Medicines Initiative
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference68 articles.
1. HTAi Global Policy Forum. Real-world evidence in the context of health technology assessment processes – from theory to action. 2018. https://htai.org/wp-content/uploads/2019/02/HTAiGlobalPolicyForum2019_BackgroundPaper.pdf
2. Franklin JM, Glynn RJ, Martin D, et al. Evaluating the use of nonrandomized real-world data analyses for regulatory decision making. Clin Pharmacol Ther. 2019;105:867–77. https://doi.org/10.1002/cpt.1351.
3. Asche CV, Seal B, Kahler KH, et al. Evaluation of healthcare interventions and big data: review of associated data issues. Pharmacoeconomics. 2017;35:759–65. https://doi.org/10.1007/s40273-017-0513-5.
4. Schneeweiss S, Brown JS, Bate A, et al. Choosing among common data models for real-world data analyses fit for making decisions about the effectiveness of medical products. Clin Pharmacol Ther. 2019. https://doi.org/10.1002/cpt.1577.
5. Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: Why and how? J Intern Med. 2014;275:551–61. https://doi.org/10.1111/joim.12159.
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献